drugset
Drugs / Narlaprevir
last change Aug 2020 re-read 2 minutes ago

Narlaprevir

also known as SCH 900518 · NVR

Small molecule

Developed for
chronic hepatitis C virus infection
Investigated by
R-Pharm · Almedis · Merck Sharp & Dohme LLC · Ascent · ChromSystemsLab · Scientific Center EFiS

Trials 7 · a red edge is where a trial was stopped

today NCT04246723 · Ph 2 NCT03485846 · Ph 2 NCT03537404 · Ph 1 NCT03833362 · Ph 3 NCT03832426 · Ph 1 NCT00797745 · Ph 2 NCT01081158 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT03537404 Apr → Jun 2017 — R-Pharm Completed No outcome recorded
Phase 1 NCT03832426 Nov 2013 → Oct 2014 — R-Pharm Completed No outcome recorded
Phase 1 NCT01081158 Jul 2007 → Aug 2008 chronic hepatitis C virus infection Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 23 trials
Phase 2 NCT04246723 May 2019 → Apr 2020 chronic hepatitis C virus infection R-Pharm Completed No outcome recorded
Phase 2 NCT03485846 Nov 2017 → Aug 2018 chronic hepatitis C virus infection R-Pharm Completed No outcome recorded
Phase 2 NCT00797745 Nov 2008 → Jul 2009 chronic hepatitis C virus infection Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 31 trial
Phase 3 NCT03833362 May 2014 → Mar 2016 chronic hepatitis C virus infection R-Pharm Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT00689390 Background Feb 2007 → Oct 2014 chronic hepatitis C virus infection Merck Sharp & Dohme LLC Terminated No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Narlaprevir ClinicalTrials.gov intervention name — accepted as the source's own label NCT00689390 ↗
5

NCT03485846 ↗

NCT03833362 ↗

NCT04246723 ↗

NCT03832426 ↗

NCT03537404 ↗
Known as NVR “In this study we sought to evaluate narlaprevir (NVR) pharmacokinetics (PK) after a single dose with or without ritonavir (RTV) in cirrhotic versus healthy subjects.” PMID 27645244 ↗ Nov 2016
Known as SCH 900518 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01081158 ↗
1

NCT00797745 ↗
Action Inhibit “SCH 900518 is a potent oral inhibitor of HCV NS3 protease” NCT00797745 ↗
Modality Small molecule — CHEMBL1255891 ↗
Route Oral “SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.” NCT00797745 ↗